Navigation Links
Human Genome Sciences and Novozymes Announce Amendment to Albumin Fusion License Agreement
Date:5/7/2009

ROCKVILLE, Md. and NOTTINGHAM, UK, May 7 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) and Novozymes Biopharma, a part of Novozymes (Nasdaq: NZYM B), today announced that they have amended an existing license agreement to allow both companies to expand application of their proprietary albumin fusion technology.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO)

Under the amended agreement, HGS and Novozymes each has the opportunity to exclusively license and/or sublicense a number of albumin fusion proteins in exchange for royalties and other consideration. No existing HGS or Novozymes products or product rights, including rights licensed to other companies, are affected by these amendments. Financial or other terms of the agreement were not disclosed.

"Genetic fusion of therapeutic proteins to albumin can improve the pharmacology of the proteins, resulting in important benefits to patients," said Barry A. Labinger, Executive Vice President and Chief Commercial Officer, HGS. "For example, with certain therapeutic proteins, albumin fusion may make it possible to dose less frequently and reduce side effects associated with injections. We are pleased to work with Novozymes to broaden the application of albumin fusion technology to new classes of proteins and peptides."

Thomas Videbaek, Executive Vice President, Novozymes, said, "We are delighted to expand this license agreement with HGS. We license both the fusion protein and the yeast expression systems, which have been optimised for producing albumin fusion proteins as the solution that provides an efficacious half-life in patients. Our strength
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)
2. New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human
3. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
4. Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development
5. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Bear Stearns Conference
9. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference
11. Premier Research Appoints Global Head of Human Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... Chosen for his engaging style ... has been selected as keynote speaker for a ... will deliver his keynote: "Don't Stop Thinking About ... to the American Medical Association, Blue Cross Blue ... Forum on Wireless Healthcare, United Healthcare, IASIS Healthcare, ...
(Date:6/1/2015)... June 1, 2015  Turing Pharmaceuticals AG announced that ... Salinas , MD, MSc,  has joined the company ... Dr. Salinas, who holds a medical degree as ... record of significant accomplishments in the pharmaceutical industry, ... Dr. Salinas has played a leadership role in ...
(Date:6/1/2015)... Research and Markets ... of the "Oxidative Stress Assay Market ... (Indirect, Enzyme-based, Reactive Oxygen Species (ROS)-based), Technology ... Global Forecast to 2020" report to ... , The global oxidative stress ...
(Date:6/1/2015)... and YONGIN, South Korea , ... pride that Green Cross Biotherapeutics Inc. (GCBT) kicked off ... located on the Montreal Technoparc,s Saint-Laurent Campus. The CA$315 ... investment projects in Canada in ... the first intravenous immunoglobulin (IVIG) and albumin manufacturing plant ...
Breaking Biology Technology:Futurist Jack Uldrich to Address the Future of Pharmaceuticals 2Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 2Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 3Oxidative Stress Assay Market 2015 - Global Forecast to 2020 2Green Cross Biotherapeutics Kicks Off Construction in Montreal 2Green Cross Biotherapeutics Kicks Off Construction in Montreal 3
... Calif., April 21 /PRNewswire-FirstCall/-- Pharmacyclics,Inc. (Nasdaq: PCYC ... staff,deficiency letter on April 17, 2008 indicating that, ... for Pharmacyclics, common stock has closed,below the minimum ... for continued,inclusion on The Nasdaq Global Market under ...
... Per Share, SAN JOSE, Calif., April 21 ... provider of medical devices,for the minimally invasive treatment of ... quarter ended March 31, 2008., Net revenues for ... compared with $15.6 million for the first quarter of ...
... CALL AND WEBCAST SCHEDULED FOR WEDNESDAY, APRIL 30, ... NBIX ) announced today that the Company will report ... closes on Wednesday,April 30, 2008. Neurocrine will host a ... and provide a Company update Wednesday,afternoon, April 30, 2008 ...
Cached Biology Technology:VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales 2VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales 3VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales 4VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales 5VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales 6VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales 7Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2008 Financial Results 2
(Date:6/1/2015)... According to a new market research report ... & Touchless), Application (Consumer Electronics, Automotive, & Others), Product ... Forecast to 2020", published by MarketsandMarkets, the Gesture Recognition ... Billion by 2020, at a CAGR of 28.23% between ... data T ables and   86   F ...
(Date:6/1/2015)... DALLAS , June 1, 2015 ... report "Next Generation Biometrics Market by Application (Government, ... Electronics, Travel & Immigration, and Security), Technology (Face ... Recognition, Signature Recognition, Vein Recognition, and Others), Function ... America , Europe , ...
(Date:5/29/2015)... May 28, 2015 Research and Markets ... the "Facial Recognition Market by Solution, by ... Forecast to 2020" report to their offering. ... facial recognition technology become more efficient and cost ... traction and investment from the commercial sector. The ...
Breaking Biology News(10 mins):Gesture Recognition & Touchless Sensing Market Worth $23.55 Billion by 2020 2Gesture Recognition & Touchless Sensing Market Worth $23.55 Billion by 2020 3Gesture Recognition & Touchless Sensing Market Worth $23.55 Billion by 2020 4Next Generation Biometrics Market Worth $24,448.84 Million by 2020 2Next Generation Biometrics Market Worth $24,448.84 Million by 2020 3Next Generation Biometrics Market Worth $24,448.84 Million by 2020 4Global advanced Facial Recognition Market Expected to Grow From $2.77 Billion in 2015 to $6.19 Billion in 2020, at an Estimated CAGR of 17.4% 2
... issue of Nature Genetics, is based on data from ... known genes, but also discovered ten new genes. Altogether ... 3.5 centimeters. The analysis produced some biologically insightful ... the microRNA let-7, which affects the regulation of other ...
... May 2008 Pediatric Academic Societies and Asian Society for ... obesity negatively impacts vascular endothelial function, which relates to ... the U.S. during the past 20 years and obesity ... incidence of obesity in children is also increasing and ...
... has swapped their comfortable offices for one of the ... a challenging field campaign that is seen as the ... mission CryoSat will be as accurate as possible. ... are currently in the middle of CryoSat Validation Experiment ...
Cached Biology News:How body size is regulated 2Study supports reason for concern in childhood and adolescent obesity 2Scientists endure Arctic for last campaign prior to CryoSat-2 launch 2Scientists endure Arctic for last campaign prior to CryoSat-2 launch 3
... multi-cell is for 2-D separations. The cell has ... PROTEAN II xi multi-cell can be customized for ... plates, and cooling system. The PROTEAN II xi ... II XL multi-cell for a wider format that ...
F40 piston seals are supplied as 2 seals with a seal tool to service one F40 pump of a BioLogic DuoFlow workstation....
... Cell permeable fluorescent minor groove-binding probe ... of double-stranded DNA (preferentially to AT rich ... approximately 20 times greater than DAPI alone. ... ethidium bromide for staining DNA in agarose ...
Mol wt: monoisotopic mol wt1,045.5423 Da by calculation...
Biology Products: